Pharma Product Overview

Oncovia™ Product Overview Precision Therapy. Powerful Results.

What is Oncovia™? 30+ Oncovia™ (Lumetrexan) is a precision-targeted therapy developed to combat advanced non-small cell lung cancer (NSCLC). Designed to selectively inhibit tumor growth while preserving healthy cells, Oncovia™ delivers superior efficacy with fewer side effects than traditional treatments. Available countries, bringing hope to millions. 68% proven increase in survival rates.

Oncovia™ (Lumetrexan) is part of Zenovara Pharmaceuticals’ cutting-edge oncology portfolio, dedicated to delivering next-generation therapies for advanced and hard-to-treat cancers. • Colorectal Cancer – promising tumor response rates. • Pancreatic Cancer – Investigating its role in mutation-driven tumor suppression. • Brain Metastases – Early data suggests potential to cross the blood-brain barrier for enhanced efficacy. With a strong clinical foundation and continued innovation, Oncovia™ is paving the way for a new era in targeted cancer treatment. Transforming cancer care

Oncovia™ is available in two precision-engineered formulations, designed to provide flexible, patient-centered treatment options based on disease severity and individual patient needs. How It Works: The oral formulation is engineered with nano-encapsulation technology, enhancing bioavailability and ensuring consistent drug delivery to cancer cells. How It Works: The IV formulation is infused over 30–60 minutes, allowing direct, high-concentration drug delivery into the system, making it ideal for hospitalized or high-risk patients requiring intensive treatment. • Once-daily dosing for easy patient compliance. • Rapid absorption in the bloodstream. • Convenient for outpatient treatment • Designed for long-term therapy 100mg Tablets – Oral Targeted Therapy • High-dose administration for aggressive tumor control. • Immediate bloodstream absorption • Recommended for advanced or metastatic cases. • Administered under medical supervision. IV Infusion – Therapy for Critical Cases Treatment for every need

Fewer Side Effects Traditional cancer treatments, such as chemotherapy, often attack both cancerous and healthy cells, leading to severe side effects and compromised quality of life. Oncovia™ takes a different approach. Targeted Therapy Improved Patient Tolerance With its high precision, improved tolerability, and AI-driven efficiency, Oncovia™ is not just another treatment—it’s a game-changer in cancer therapy. Empowering Patients & Physicians This approach accelerated the discovery process, enabling faster clinical trials and regulatory approval, bringing Oncovia™ to patients years ahead of traditional development timelines. Map genetic mutations Data-Driven Innovation Optimize drug formulation Our special approach

Parameter Oncovia™ Standard EGFR-TKIs Chemotherapy Progression-Free Survival (PFS) 14.2 months 9.6 months 5.2 months Overall Response Rate (ORR) 75% 56% 37% Severe Side Effects (Grade 3-4) 8% 21% 45% Time to Tumor Reduction 6 weeks 10 weeks 14 weeks Rapid response in lung cancer

Expanding Oncovia™: New Research & Clinical Trials At Zenovara Pharmaceuticals, we are committed to continuous innovation in cancer treatment. Oncovia™ is just the beginning—our research pipeline is focused on expanding indications, enhancing drug efficacy, and exploring next-generation combination therapies. • Regulatory submissions in 10+ new countries by next year. • Affordable treatment programs for low-income regions. • Collaboration with top cancer research institutions to accelerate discoveries. • Phase III Trials for Additional Indications • Evaluating Oncovia™ in combination with immunotherapy. • Studying efficacy in EGFR-mutant pancreatic tumors. • Investigating ability to cross the blood-brain barrier.